Contact
searchSearch
HMP Global

Hepatology Topic Center

Featured Article

Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Drug Safety
UDCA Use Linked to Lower Cancer Risk in Primary Biliary Cholangitis, Large EHR Study Finds
01/14/2026
Jessica Garlewicz
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
For practicing...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Research Highlights
Liquid Biopsy Shows Potential in Cholangiocarcinoma Care
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology
Research Highlights
Immunogenomic Insights Transform Understanding of Cholangiocarcinoma
10/03/2025
Rebecca Mashaw
By integrating genomic and immunologic perspectives, a recent study reviews ways in which immune dysfunction and genomic alterations may drive tumor initiation, progression, and therapeutic response in cholangiocarcinoma.
By integrating genomic and immunologic perspectives, a recent study reviews ways in which immune dysfunction and genomic alterations may drive tumor initiation, progression, and therapeutic response in cholangiocarcinoma.
By integrating genomic and...
10/03/2025
Gastroenterology
Research Highlights
Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma
10/01/2025
Allison Casey
Hepatic arterial infusion pump (HAIP) chemotherapy combined with systemic chemotherapy was associated with a favorable 3-year overall survival compared to systemic chemotherapy alone for patients with advanced intrahepatic cholangiocarcinoma.
Hepatic arterial infusion pump (HAIP) chemotherapy combined with systemic chemotherapy was associated with a favorable 3-year overall survival compared to systemic chemotherapy alone for patients with advanced intrahepatic cholangiocarcinoma.
Hepatic arterial infusion pump...
10/01/2025
Gastroenterology
Research Highlights
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
10/01/2025
Stephanie Holland
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized,...
10/01/2025
Gastroenterology
News
Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma
10/01/2025
Allison Casey
Stereotactic body radiotherapy did not show an advantage over chemotherapy alone in progression-free survival but there was a longer median overall survival time and better primary tumor control without additional safety concerns.
Stereotactic body radiotherapy did not show an advantage over chemotherapy alone in progression-free survival but there was a longer median overall survival time and better primary tumor control without additional safety concerns.
Stereotactic body radiotherapy...
10/01/2025
Gastroenterology

Videos

Blanca Lizaolo-Mayo
Video
How I Treat NASH (MASH)
11/15/2024
Blanca Lizaolo-Mayo, MD
Dr Lizaolo-Mayo discusses factors to consider when diagnosing and treating patients without obesity or overweight who may have metabolic-associated steatohepatitis (MASH).
Dr Lizaolo-Mayo discusses factors to consider when diagnosing and treating patients without obesity or overweight who may have metabolic-associated steatohepatitis (MASH).
Dr Lizaolo-Mayo discusses...
11/15/2024
Gastroenterology
Video
Kayla Monks, MS, RD, on Nutrition for Patients With Liver Disease
06/14/2024
Kayla Monks, MS, RD
Kayla Monks, MS, RD, discusses nutritional needs and challenges of patients with liver disease, including candidates for transplant, and how to work with patients to achieve the best possible outcomes.
Kayla Monks, MS, RD, discusses nutritional needs and challenges of patients with liver disease, including candidates for transplant, and how to work with patients to achieve the best possible outcomes.
Kayla Monks, MS, RD, discusses...
06/14/2024
Gastroenterology
Videos
Lauren Yang, MD, on Hepatitis B Research
12/01/2020
In this video, Lauren Yang, MD, from Beth Israel Deaconess Medical Center, discusses what learned at the recent American Association for the Study of Liver Diseases annual meeting about research into managing hepatitis B.
In this video, Lauren Yang, MD, from Beth Israel Deaconess Medical Center, discusses what learned at the recent American Association for the Study of Liver Diseases annual meeting about research into managing hepatitis B.
In this video, Lauren Yang, MD,...
12/01/2020
Gastroenterology
Medication
Medical Therapies for IBS-C: Expert Roundtable Part 3
01/29/2026
Anthony Lembo, MD; Megan Riehl, PsyD; Brooks D. Cash, MD
Our expert panel continues as Drs Cash, Lembo, and Riehl delve into the existing medications available to treat IBS-C, from neuromodulators to secretagogues and the sodium/hydrogen exchanger (NHE3) inhibitor tenapanor.
Our expert panel continues as Drs Cash, Lembo, and Riehl delve into the existing medications available to treat IBS-C, from neuromodulators to secretagogues and the sodium/hydrogen exchanger (NHE3) inhibitor tenapanor.
Our expert panel continues as...
01/29/2026
Gastroenterology
Treatment Guidance
Managing MASLD and MASH: Expert Roundtable Part 4
01/27/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
As hepatologists Nezam Afdhal, Meena Bansal, and Zobair Younossi continue their expert roundtable, the topic turns to the management of MASLD and MASH, including the best use of two new types of drugs--resmetirom and the GLP-1 agonists.
As hepatologists Nezam Afdhal, Meena Bansal, and Zobair Younossi continue their expert roundtable, the topic turns to the management of MASLD and MASH, including the best use of two new types of drugs--resmetirom and the GLP-1 agonists.
As hepatologists Nezam Afdhal,...
01/27/2026
Gastroenterology
Expert Insights
When to Refer Patients to Hepatology for MASLD/MASH
01/27/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
The expert panel on MASLD and MASH continues its discussion with guidance on when a patients with suspected steatotic liver disease should be referred to a hepatology specialist.
The expert panel on MASLD and MASH continues its discussion with guidance on when a patients with suspected steatotic liver disease should be referred to a hepatology specialist.
The expert panel on MASLD and...
01/27/2026
Gastroenterology
Patient Treatment
Treating IBS-C: Expert Roundtable Part 2
01/23/2026
Anthony Lembo, MD; Brooks D. Cash, MD; Megan Riehl, PsyD
In part 2 of this roundtable series, Drs Anthony Lembo, Megan Riehl, and Brooks Cash review the varieties of treatments available for irritable bowel syndrome-constipation, including diet, lifestyle modifications, and medication.
In part 2 of this roundtable series, Drs Anthony Lembo, Megan Riehl, and Brooks Cash review the varieties of treatments available for irritable bowel syndrome-constipation, including diet, lifestyle modifications, and medication.
In part 2 of this roundtable...
01/23/2026
Gastroenterology
Diagnostics
Diagnosing IBS-C: Expert Roundtable Part 1
01/22/2026
Anthony Lembo, MD; Megan Riehl, PsyD; Brooks D. Cash, MD
Diagnosing irritable bowel syndrome with constipation can be challenging. In this video, Drs Anthony Lembo, Brooks Cash, and Megan Riehl discuss the importance and the tests required to make a positive diagnosis rather than a diagnosis of...
Diagnosing irritable bowel syndrome with constipation can be challenging. In this video, Drs Anthony Lembo, Brooks Cash, and Megan Riehl discuss the importance and the tests required to make a positive diagnosis rather than a diagnosis of...
Diagnosing irritable bowel...
01/22/2026
Gastroenterology
Hilary Ugras
Clinical Pearls
Hilary Ugras, NP, on IBS-C Medical Therapies
01/21/2026
Hilary Ugras, NP
Hilary Ugras, NP, reviews the types of medical therapies available for treating IBS-C and how to position them in treating patients.
Hilary Ugras, NP, reviews the types of medical therapies available for treating IBS-C and how to position them in treating patients.
Hilary Ugras, NP, reviews the...
01/21/2026
Gastroenterology
Expert Insights
Screening for MASLD and MASH: Expert Roundtable Part 2
01/19/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 2 of this expert roundtable Drs Afdhal, Bansal, and Younossi discuss how to determine which patients need to be screened for MASLD/MASH, how to conduct screening, and which modalities are best.
In Part 2 of this expert roundtable Drs Afdhal, Bansal, and Younossi discuss how to determine which patients need to be screened for MASLD/MASH, how to conduct screening, and which modalities are best.
In Part 2 of this expert...
01/19/2026
Gastroenterology
Expert Insights
Expert Roundtable on MASLD/MASH: Part 1
01/15/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart...
01/15/2026
Gastroenterology
Kim Orleck
Clinical Pearls
Kimberly Orleck, PA, on Diagnosing IBS-C
01/13/2026
Kimberly Orleck, ANP-BC
Kimberly Orleck, ANP-BC, reviews the key points to consider when diagnosing a patient with constipation to determine if the condition is irritable bowel syndrome with predominant constipation.
Kimberly Orleck, ANP-BC, reviews the key points to consider when diagnosing a patient with constipation to determine if the condition is irritable bowel syndrome with predominant constipation.
Kimberly Orleck, ANP-BC, reviews...
01/13/2026
Gastroenterology
Sid Barritt
How I Treat
How I Treat MASLD/MASH: Dr Sidney Barritt on Pharmacotherapy
01/08/2026
A. Sidney Barritt, MD
Dr Barritt discusses how he approaches the treatment of MASLD and MASH, both with medical therapies and lifestyle adaptations.
Dr Barritt discusses how he approaches the treatment of MASLD and MASH, both with medical therapies and lifestyle adaptations.
Dr Barritt discusses how he...
01/08/2026
Gastroenterology

News

Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Research Highlights
Liquid Biopsy Shows Potential in Cholangiocarcinoma Care
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology
Research Highlights
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
10/01/2025
Stephanie Holland
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized,...
10/01/2025
Gastroenterology
Research Highlights
Incidence of Hepatocellular Carcinoma in MASLD Patients Quantified in Large Meta-Analysis
09/15/2025
Rebecca Mashaw
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight...
09/15/2025
Gastroenterology
FDA Alert
Obeticholic Acid Withdrawn From US Market for PBC; FDA Puts Clinical Trials on Hold
09/15/2025
Rebecca Mashaw
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will...
09/15/2025
Gastroenterology
News
Hypertension Linked to Liver Disease Progression and Adverse Outcomes in MASLD
09/04/2025
Jessica Garlewicz
Across three large prospective cohorts, hypertension was consistently associated with worse liver-related and systemic outcomes.
Across three large prospective cohorts, hypertension was consistently associated with worse liver-related and systemic outcomes.
Across three large prospective...
09/04/2025
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology
Research Highlights
Short Course Radiation and ctDNA for Rectal Cancer
01/14/2026
Jessica Garlewicz
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the...
01/14/2026
Gastroenterology
Research Highlights
Cumulative Social Risk Linked to Poorer Survival in Stage III Colorectal Cancer
01/14/2026
Jessica Garlewicz
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Conference Coverage
E-Cigarette Use and Risk of Peptic Ulcer Disease: Findings from a National Cohort
10/27/2025
Rebecca Mashaw
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at...
10/27/2025
Gastroenterology
Research Highlights
Liquid Biopsy Shows Potential in Cholangiocarcinoma Care
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology

News

Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Research Highlights
Liquid Biopsy Shows Potential in Cholangiocarcinoma Care
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology
Research Highlights
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
10/01/2025
Stephanie Holland
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of tinengotinib for refractory/relapsed cholangiocarcinoma.
An ongoing randomized,...
10/01/2025
Gastroenterology
Research Highlights
Incidence of Hepatocellular Carcinoma in MASLD Patients Quantified in Large Meta-Analysis
09/15/2025
Rebecca Mashaw
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight...
09/15/2025
Gastroenterology
FDA Alert
Obeticholic Acid Withdrawn From US Market for PBC; FDA Puts Clinical Trials on Hold
09/15/2025
Rebecca Mashaw
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will...
09/15/2025
Gastroenterology
News
Hypertension Linked to Liver Disease Progression and Adverse Outcomes in MASLD
09/04/2025
Jessica Garlewicz
Across three large prospective cohorts, hypertension was consistently associated with worse liver-related and systemic outcomes.
Across three large prospective cohorts, hypertension was consistently associated with worse liver-related and systemic outcomes.
Across three large prospective...
09/04/2025
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology
Research Highlights
Short Course Radiation and ctDNA for Rectal Cancer
01/14/2026
Jessica Garlewicz
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the...
01/14/2026
Gastroenterology
Research Highlights
Cumulative Social Risk Linked to Poorer Survival in Stage III Colorectal Cancer
01/14/2026
Jessica Garlewicz
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Conference Coverage
E-Cigarette Use and Risk of Peptic Ulcer Disease: Findings from a National Cohort
10/27/2025
Rebecca Mashaw
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at...
10/27/2025
Gastroenterology
Research Highlights
Liquid Biopsy Shows Potential in Cholangiocarcinoma Care
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use